Jason  Duncan net worth and biography

Jason Duncan Biography and Net Worth

Insider of Albireo Pharma
Mr. Duncan joins Albireo with more than 15 years of legal and compliance experience in the pharmaceutical industry. He most recently served as General Counsel at Stallergenes Greer, where he oversaw all legal activities for the allergy immunotherapy company’s Americas business. Previously, Mr. Duncan was Vice President, Head of Compliance and Legal for Sobi, a global biopharmaceutical company focused on rare inflammatory and genetic diseases. At Sobi, Mr. Duncan was responsible for all legal and compliance matters for the company’s North American affiliates, and served on the leadership team. Prior to Sobi, Mr. Duncan held roles of increasing responsibility at EMD Serono, culminating in his position as Associate General Counsel for Neurology and Discovery.

What is Jason Duncan's net worth?

The estimated net worth of Jason Duncan is at least $688,166.05 as of July 25th, 2022. Mr. Duncan owns 15,587 shares of Albireo Pharma stock worth more than $688,166 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Duncan may own. Learn More about Jason Duncan's net worth.

How do I contact Jason Duncan?

The corporate mailing address for Mr. Duncan and other Albireo Pharma executives is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. Albireo Pharma can also be reached via phone at (857) 254-5555 and via email at [email protected]. Learn More on Jason Duncan's contact information.

Has Jason Duncan been buying or selling shares of Albireo Pharma?

Jason Duncan has not been actively trading shares of Albireo Pharma during the last ninety days. Most recently, Jason Duncan sold 313 shares of the business's stock in a transaction on Monday, July 25th. The shares were sold at an average price of $23.88, for a transaction totalling $7,474.44. Following the completion of the sale, the insider now directly owns 15,587 shares of the company's stock, valued at $372,217.56. Learn More on Jason Duncan's trading history.

Who are Albireo Pharma's active insiders?

Albireo Pharma's insider roster includes Ronald Cooper (CEO), Jason Duncan (Insider), Simon Harford (CFO), Patrick Horn (Insider), Jan Mattsson (Insider), and Pamela Stephenson (insider). Learn More on Albireo Pharma's active insiders.

Jason Duncan Insider Trading History at Albireo Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2022Sell313$23.88$7,474.4415,587View SEC Filing Icon  
4/25/2022Sell312$33.43$10,430.1616,008View SEC Filing Icon  
1/24/2022Sell1,688$24.94$42,098.72View SEC Filing Icon  
10/25/2021Sell217$29.21$6,338.57View SEC Filing Icon  
4/22/2021Sell90$31.75$2,857.50View SEC Filing Icon  
4/1/2021Sell300$36.16$10,848.00View SEC Filing Icon  
1/22/2021Sell110$34.62$3,808.20View SEC Filing Icon  
7/22/2020Sell91$25.80$2,347.80View SEC Filing Icon  
See Full Table

Jason Duncan Buying and Selling Activity at Albireo Pharma

This chart shows Jason Duncan's buying and selling at Albireo Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Albireo Pharma Company Overview

Albireo Pharma logo
Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $44.15
Low: $43.99
High: $44.90

50 Day Range

MA: $44.17
Low: $43.50
High: $44.95

2 Week Range

Now: $44.15
Low: $16.02
High: $45.23

Volume

1,241,200 shs

Average Volume

704,539 shs

Market Capitalization

$913.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03